Prothelia is developing recombinant human laminin-111 (RHLAM-111) for treatment of Congenital Muscular Dystrophy Type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin Deficiency, or LAMA2 Deficiency.

Milford, MA, USA

Boston, MA, USA

West Street / River Street, Boston, MA, USA

Prothelia

Originally established as the venture capital arm of the Rockefeller family in 1969, Venrock partners with entrepreneurs to build some of the world's most disruptive, successful companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Millennium Pharma, Nest, SlideShare and Tudou.

Venrock

Join a Venrock portfolio company

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Venrock Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Venrock network as they come up.

You can always update this information later.

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Venrock company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.